HER3 Overexpression and Survival in Solid Tumors: A Meta-analysis

来自 EBSCO

阅读量：

作者：

O Alberto，VB Francisco，S Bostjan，T Arnoud，P Atanasio，A Eitan

展开

摘要：

Background The human epidermal growth factor receptor 3 (HER3) is an ErbB/HER family member that dimerizes with other ErbB receptors such as HER2. Numerous agents against HER3 are in clinical development despite variable data for the prognostic impact of HER3 expression. Here we report a meta-analysis of the association of HER3 expression and survival in solid tumors.Methods PubMed was searched for studies evaluating expression of HER3 (as measured by immunohistochemistry) and overall survival (OS) in solid tumors. Published data were extracted and computed into odds ratios (ORs) for death at 3 and 5 years. Data were pooled using the Mantel-Haenszel random-effect model. All statistical tests were two-sided.Results Analysis included 12 studies: three that evaluated colorectal cancer, two that evaluated gastric cancer, two that evaluated breast cancer, and one each that evaluated melanoma, ovarian cancer, head and neck cancer, pancreatic cancer, and cervical cancer. The median percentage of cancers with HER3 overexpression was 42.2%. HER3 was associated with worse OS at both 3 years (OR = 2.24, 95% confidence interval [CI] = 1.77 to 2.83, P Conclusions Expression of HER3 is associated with worse survival in solid tumors. The influence of HER3 may be greater in those tumors where HER2 is commonly overexpressed. J Natl Cancer Inst;2013;105:266-273

展开

关键词：

EPIDERMAL-GROWTH-FACTOR RECEPTOR TYROSINE KINASES ERBB SIGNALING NETWORK PROGNOSTIC-SIGNIFICANCE OVARIAN-CANCER BREAST-CANCER DECREASED SURVIVAL POOR-PROGNOSIS EXPRESSION